Kura Oncology, Inc. cash flow to debt ratio of -313.13% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Kura Oncology, Inc.'s free cash flow has decreased 152.82% from $133.84M last year to $-70.70M, signaling decreasing performance

Kura Oncology, Inc.'s debt to equity ratio is 0.23, which means that the company's assets are healthy financed, signaling financial stability.

Kura Oncology, Inc.'s debt has increased relative to shareholder equity from 0.04 last year to 0.23 today, signaling weakened financials

Kura Oncology, Inc. has a net cash position, so leverage is healthy.

Kura Oncology, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Kura Oncology, Inc.'s profit margin has decreased (27.35%) in the last year from -322.89% to -411.19%, signaling decreasing performance

Kura Oncology, Inc.'s short-term assets of $708.66M exceed its short-term liabilities of $116.97M

Kura Oncology, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Kura Oncology, Inc.'s return on equity of -141.95%, is lower than 15.00%, indicating bad performance

Kura Oncology, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Kura Oncology, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Kura Oncology, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Kura Oncology, Inc. has negative free cash flow, indicating cash burn

Kura Oncology, Inc.'s yearly earnings has decreased 60.17% since last year from $-173.98M to $-278.67M, signaling decreasing performance

Kura Oncology, Inc.'s yearly revenue has increased 25.24% since last year from $53.88M to $67.48M, signaling increasing performance

ROIC -57.53% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Kura Oncology, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Kura Oncology, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Kura Oncology, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Kura Oncology, Inc. has insufficient data to evaluate this check.

Kura Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kura Oncology, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Kura Oncology, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Kura Oncology, Inc. has insufficient data to evaluate this check.

Kura Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Kura Oncology, Inc. has a price-to-book ratio of 8.09x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Kura Oncology, Inc. has a price-to-sales ratio of 12.18x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue